The Impact of ANxA6 Gene Polymorphism on the Efficacy of Methotrexate Treatment in Psoriasis Patients
- 12 February 2021
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 237 (4), 579-587
- https://doi.org/10.1159/000514072
Abstract
Background: There are great interindividual variations in the clinical efficacy of methotrexate (MTX) treatment and patients’ genetic background seems promising in its explanation. Objectives: The study aimed to test whether the polymorphism of annexin A6 (ANxA6) gene, a susceptibility factor for psoriasis, was associated with the clinical response to MTX therapy. Methods: A total of 325 patients enrolled in the study received oral MTX treatment, of whom 310 completed the 1-year study and performed the genotype analysis. They were defined as responders (a reduction of Psoriasis Area and Severity Index [PASI] score ≥75%) and nonresponders (a reduction of PASI Results: We found significant associations for the ANxA6 SNPs of rs11960458, rs960709, and rs13168551 with psoriasis severity. Patients with rs11960458 CC genotype and rs960709 GG genotype showed higher percentages of PASI75 and improvement rates of PASI at 12 weeks. And on 1-year treatment, statistical difference occurred in rs11960458 rather than other SNPs compared between responders and nonresponders that the frequency of CC genotype was higher in responders (p = 0.019). After adjustment for potential confounders, patients with rs11960458 TT/CT genotype (at 12 weeks: OR 0.483, 95% CI 0.245–0.951, p = 0.035; at 1 year: OR 0.483, 95% CI 0.280–0.833, p = 0.009) were significantly more likely to not respond to MTX both on the short-term and long-term treatment, while rs960709 and rs13168551 polymorphisms were only associated with the short-term efficacy of MTX (p = 0.018 and p = 0.036, respectively). Conclusions: The CC genotype of ANxA6 (rs11960458) was significantly associated with a better response when compared to those patients with the TT/CT genotype, thus being a potential predictor for the clinical efficacy of MTX.Keywords
This publication has 22 references indexed in Scilit:
- Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published TrialsPLOS ONE, 2016
- Candidate gene polymorphisms and risk of psoriasis: A pilot studyExperimental and Therapeutic Medicine, 2016
- Systemic methotrexate for the treatment of psoriasisExpert Review of Clinical Immunology, 2015
- Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studiesBritish Journal of Dermatology, 2014
- Annexin A6 Interacts With p65 and Stimulates NF‐κB Activity and Catabolic Events in Articular ChondrocytesArthritis & Rheumatism, 2013
- TNIP1/ANXA6 and CSMD1 variants interacting with cigarette smoking, alcohol intake affect risk of psoriasisJournal of Dermatological Science, 2013
- NF-κB: An essential transcription factor in psoriasisJournal of Dermatological Science, 2013
- Annexin A6 is an organizer of membrane microdomains to regulate receptor localization and signallingIUBMB Life, 2011
- Association analyses identify six new psoriasis susceptibility loci in the Chinese populationNature Genetics, 2010
- Expression of Early and Late Differentiation Markers (Proliferating Cell Nuclear Antigen, Syndecan-3, Annexin VI, and Alkaline Phosphatase) by Human Osteoarthritic ChondrocytesThe American Journal of Pathology, 2001